Pfizer And BioNTech Provide Update On mRNA-based Combination Vaccine Program Against Influenza And COVID-19: Says In A Phase 3 Trial, Vaccine Candidate Met One Of Its Two Primary Immunogenicity Objectives
Portfolio Pulse from Benzinga Newsdesk
Pfizer and BioNTech provided an update on their mRNA-based combination vaccine program against influenza and COVID-19. In a Phase 3 trial, the vaccine candidate met one of its two primary immunogenicity objectives but did not meet the objective for non-inferiority against the influenza B strain. The companies are evaluating adjustments and will discuss next steps with health authorities. Pfizer also reported encouraging data from a separate Phase 2 trial of a second-generation trivalent influenza mRNA vaccine.
August 16, 2024 | 10:50 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BioNTech, in collaboration with Pfizer, reported that their mRNA-based combination vaccine met one of its primary objectives in a Phase 3 trial but did not meet the objective for non-inferiority against the influenza B strain. The companies are evaluating adjustments and will discuss next steps with health authorities.
The mixed results from the Phase 3 trial may create uncertainty for BioNTech, but the ongoing evaluation and potential adjustments could mitigate negative impacts. The short-term impact on BioNTech's stock is likely to be neutral.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
Pfizer's mRNA-based combination vaccine met one of its primary objectives in a Phase 3 trial but failed to meet the objective for non-inferiority against the influenza B strain. The company is evaluating adjustments and will discuss next steps with health authorities. Additionally, Pfizer's separate Phase 2 trial of a second-generation trivalent influenza mRNA vaccine showed robust immunogenicity.
The mixed results from the Phase 3 trial may create uncertainty, but the encouraging data from the Phase 2 trial could offset some concerns. The overall impact on Pfizer's stock is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100